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CHOP versus GEM-P in previously untreated patients with 
peripheral T-cell lymphoma (CHEMO-T): a phase 2, 
multicentre, randomised, open-label trial
Mary Gleeson, Clare Peckitt, Ye Mong To, Laurice Edwards, Jacqueline Oates, Andrew Wotherspoon, Ayoma D Attygalle, Imene Zerizer, 
Bhupinder Sharma, Sue Chua, Ruwaida Begum, Ian Chau, Peter Johnson, Kirit M Ardeshna, Eliza A Hawkes, Marian P Macheta, Graham P Collins, 
John Radford, Adam Forbes, Alistair Hart, Silvia Montoto, Pamela McKay, Kim Benstead, Nicholas Morley, Nagesh Kalakonda, Yasmin Hasan, 
Deborah Turner, David Cunningham
Summary
Background Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like 
chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, 
and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients.
Methods We did a phase 2, parallel-group, multicentre, open-label randomised trial in 47 hospitals: 46 in the UK and 
one in Australia. Participants were patients aged 18 years and older with bulky (tumour mass diameter >10 cm) stage I 
to stage IV disease (WHO performance status 0–3), previously untreated peripheral T-cell lymphoma not otherwise 
speciied, angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase-negative anaplastic large cell 
lymphoma, enteropathy-associated T-cell lymphoma, or hepatosplenic γδ T-cell lymphoma. We randomly assigned 
patients (1:1) stratiied by subtype of peripheral T-cell lymphoma and international prognostic index to either CHOP 
(intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and vincristine 1·4 mg/m² [maximum 2 mg] on 
day 1, and oral prednisolone 100 mg on days 1–5) every 21 days for six cycles; or GEM-P (intravenous gemcitabine 
1000 mg/m² on days 1, 8, and 15, cisplatin 100 mg/m² on day 15, and oral or intravenous methylprednisolone 1000 mg 
on days 1–5) every 28 days for four cycles. The primary endpoint was the proportion of patients with a CT-based 
complete response or unconirmed complete response on completion of study chemotherapy, to detect a 20% 
superiority of GEM-P compared with CHOP, assessed in all patients who received at least one cycle of treatment and 
had an end-of-treatment CT scan or reported clinical progression as the reason for stopping trial treatment. Safety 
was assessed in all patients who received at least one dose of study medication. This trial is registered with 
ClinicalTrials.gov (NCT01719835) and the European Clinical Trials Database (EudraCT 2011-004146-18).
Findings Between June 18, 2012, and Nov 16, 2016, we randomly assigned 87 patients to treatment, 43 to CHOP and 
44 to GEM-P. A planned unmasked review of eicacy data by the independent data monitoring committee in 
November, 2016, showed that the number of patients with a conirmed or unconirmed complete response with 
GEM-P was non-signiicantly inferior compared with CHOP and the trial was closed early. At a median follow-up of 
27·4 months (IQR 16·6–38·4), 23 patients (62%) of 37 assessable patients assigned to CHOP had achieved a complete 
response or unconirmed complete response compared with 17 (46%) of 37 assigned to GEM-P (odds ratio 0·52, 95% 
CI 0·21–1·31; p=0·164). The most common adverse events of grade 3 or worse in both groups were neutropenia 
(17 [40%] with CHOP and nine [20%] with GEM-P), thrombocytopenia (4 [10%] with CHOP and 13 [30%] with GEM-P, 
and febrile neutropenia (12 [29%] with CHOP and 3 [7%] with GEM-P). Two patients (5%) died during the study, both 
in the GEM-P group, from lung infections.
Interpretation The number of patients with a complete response or unconirmed complete response did not difer 
between the groups, indicating that GEM-P was not superior for this outcome. CHOP should therefore remain the 
reference regimen for previously untreated peripheral T-cell lymphoma.
Funding Bloodwise and the UK National Institute of Health Research.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Peripheral T-cell lymphoma is a rare and heterogeneous 
subgroup of non-Hodgkin lymphomas, and comprises 
approximately 10% of all non-Hodgkin lymphomas in 
Europe and America.1 Randomised prospective trials in 
patients with peripheral T-cell lymphoma are scarce and 
hence there is no consensus on the optimal chemotherapy 
for previously untreated patients, although combination 
chemotherapy with cyclo- phosphamide, doxorubicin, 
vincristine, and prednisolone (CHOP) is widely used, with 
consolidative autologous stem-cell transplantation 
considered in eligible patients. However, for most patients, 
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outcomes with CHOP are poor, with only 33% to 43% 
achieving a complete response2–4 and 38·5% achieving 
5-year overall survival;5 therefore, a superior upfront 
regimen for peripheral T-cell lymphoma is urgently 
required. Previous evidence suggested that the addition of 
etoposide to CHOP (CHOEP) might improve event-free 
survival for younger patients (aged ≤60 years) without 
increased lactate dehydrogenase,6 but no beneit for 
overall survival was apparent and this approach is not 
widely applicable.
The nucleoside analogue gemcitabine is not eluxed by 
the multidrug resistance gene-1–P glycoprotein (MDR-1–
Pgp), which is overexpressed in some peripheral T-cell 
lymphomas7,8 on the tumour cells, residual lympho cytes, 
or in the endothelium8 and has shown activity both as 
monotherapy9–11 and in combination with platinum and 
steroids12–20 in patients with relapsed or refractory 
peripheral T-cell lymphoma. The regimen of intravenous 
gemcitabine 1000 mg/m² on days 1, 8, and 15 of a cycle, 
intravenous cisplatin 100 mg/m² on day 15, and oral or 
intravenous methylprednisolone 1000 mg on days 1–5 
(GEM-P) administered every 28 days is associated with 
69% to 100% of pretreated patients with peripheral T-cell 
lymphoma achieving an objective response, and 19% to 
50% achieving a complete response;14–16 a median 
progression-free survival of 12 months has been reported 
in the largest retrospective series.16
Given the poor outcomes associated with CHOP as 
front-line therapy in peripheral T-cell lymphoma and the 
promising data in relapsing and refractory peripheral 
Research in context
Evidence before this study
CHOP combination chemotherapy (cyclophosphamide, 
doxorubicin, vincristine, and prednisolone) is widely used for 
treatment of peripheral T-cell lymphoma; however, outcomes 
with CHOP are poor for most patients. We investigated GEM-P 
chemotherapy (gemcitabine, methylprednisolone, and 
cisplatin) compared with CHOP in previously untreated patients 
with peripheral T-cell lymphoma. We searched PubMed on 
Dec 4, 2017, for English-language articles published from 
January, 1998, to October, 2017, and searched abstracts from 
the American Society of Hematology and American Society of 
Clinical Oncology published between 2015–17 with the search 
terms “T-cell lymphoma”, “chemotherapy”, and “gemcitabine”, 
excluding studies in which patients with non-nodal peripheral 
T-cell lymphoma forms were assessed exclusively. We identified 
30 reports showing activity of gemcitabine in peripheral T-cell 
lymphoma; three with gemcitabine as monotherapy and nine 
with a combination of gemcitabine with platinum and steroids 
predominantly in pretreated populations, including three 
retrospective reports on GEM-P specifically in peripheral T-cell 
lymphoma. Different combinations of gemcitabine with other 
novel drugs, with or without the addition of platinum, in the 
treatment of peripheral T-cell lymphoma were also reported in 
the scientific literature, including one randomised trial that 
assessed the combination of gemcitabine, cisplatin, 
prednisolone and thalidomide versus CHOP in treatment-naive 
patients. However, there were no reported randomised studies 
on the combination of gemcitabine, platinum, and steroids 
alone versus CHOP in the front-line setting.
Added value of this study
Our phase 2 trial is one of the few randomised studies in 
previously untreated patients with peripheral T-cell lymphoma 
and is an important addition to the evidence-base. The findings 
confirm the poor outcomes for peripheral T-cell lymphoma 
within a prospective trial cohort and indicate that CHOP should 
remain the reference regimen at present. Our trial was the first 
prospective study to assess an ¹⁸F-FDG-PET-CT response in 
patients with peripheral T-cell lymphoma as part of a 
pre-planned substudy, and the data suggest that 
¹⁸F-FDG-PET-CT might be a more sensitive tool than contrast-
enhanced CT for determining response in peripheral T-cell 
lymphoma, as it might better distinguish between a residual 
fibrotic mass present after chemotherapy versus viable tumour. 
Furthermore, obtaining a complete response by ¹⁸F-FDG-PET-CT 
was independently prognostic for superior progression-free 
survival in multivariable analysis, whereas complete response by 
CT was not. Additionally, we reported the incidence and pattern 
of CNS relapse in peripheral T-cell lymphoma from a prospective 
trial. Determination of the subtype of peripheral T-cell 
lymphoma in our study was revised for around a fifth of the 
patients, highlighting the diagnostic challenges in peripheral 
T-cell lymphoma. Despite GEM-P showing non-significant 
inferiority for the endpoint of CT-based confirmed and 
unconfirmed complete response compared with CHOP, there 
were no differences in either progression-free survival or overall 
survival between the groups; future study design in this 
indication should be powered for primary endpoints of survival 
rather than complete response, which might not be an accurate 
surrogate endpoint (particularly when assessed by contrast-
enhanced CT) in peripheral T-cell lymphoma.
Implications of all the available evidence
Taken together, current evidence supports the use of 
gemcitabine as an effective therapy in the management of 
peripheral T-cell lymphoma. However, our randomised phase 2 
study did not suggest superiority of GEM-P over CHOP in the 
front-line setting for previously untreated patients and 
therefore, CHOP should remain the reference regimen in this 
indication for previously untreated patients. Although GEM-P 
has shown efficacy in patients with peripheral T-cell lymphoma, 
at present it should be reserved for patients with relapsed or 
refractory disease. A superior upfront induction regimen is 
urgently required for patients with treatment-naive peripheral 
T-cell lymphoma, and future incorporation of novel drugs could 
enhance the efficacy of front-line therapy in this indication. Trials 
are ongoing (ClinicalTrials.gov NCT01777152, NCT01796002, 
and NCT02561273) to address this research question.
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T-cell lymphoma with GEM-P, the UK National Cancer 
Research Institute (NCRI) Lymphoma Clinical Study 
Group started the CHEMO-T trial in 2012 to investigate 
the potential superiority of GEM-P compared with CHOP 
in previously untreated patients with peripheral T-cell 
lymphoma.
Methods
Study design and participants
We did a phase 2, parallel-group, multicentre, open-
label randomised trial at 47 hospitals: 46 in the UK and 
one in Australia (appendix pp 1–2). 
Eligible participants were patients aged 18 years and 
older with previously untreated histologically conirmed 
peripheral T-cell lymphoma of the WHO 2008 subtypes:21 
peripheral T-cell lymphoma not otherwise speciied, 
angioimmunoblastic T-cell lymphoma, anaplastic lymph-
oma kinase (ALK) negative anaplastic large cell T-cell 
lymphoma, enteropathy-associated T-cell lymphoma, and 
hepatosplenic γδ T-cell lymphoma.
For participation in the study, patients were required 
to have bulky stage I (tumour mass diameter >10 cm) to 
stage IV disease; a WHO performance status of 0–3 
(patients with a performance status of 3 were only 
eligible if this was deemed to be related to a lymphoma); 
adequate cardiac, renal, hepatic, and bone marrow 
function (absolute neutrophil count ≥1·0 × 10⁹/L, 
white blood cell count ≥3·0 × 10⁹/L, platelet count 
≥100·0 × 10⁹/L, and haemoglobin concentration 
≥9·0 g/dL unless related to disease). Patients with CNS 
or leptomeningeal involvement, positive serology for 
HIV-1, active hepatitis B or C, or a history of malignancy 
within the preceding 5 years (with the exception of 
curatively treated skin cancers or carcinoma in situ of 
the cervix) and poorly controlled diabetes or other 
comorbidities which would preclude the safe delivery of 
treatment within the trial, were ineligible, as were 
patients without at least one site of measurable disease 
at baseline (measurable in two perpendicular dimensions 
and ≥1 cm on the longest diameter on contrast-enhanced 
CT scan, except for patients with enteropathy-associated 
T-cell lymphoma following complete surgical resection). 
Corticosteroids, not exceeding a maximum of 
prednisolone 100 mg/day (or equivalent corticosteroid 
dose) for 7 days, for symptoms related to lymphoma 
before starting study treatment were permitted, but 
preferably not instituted before an ¹⁸F-luoro-
deoxyglucose (FDG) PET-CT scan at baseline. If cortico-
steroids were instituted before the baseline scan, they 
were required to be discontinued 24 h beforehand and 
patients were required to have a serum glucose 
concentration of 8·0 mmol/L or lower immediately 
before the scan. 
The protocol was approved by the UK Medicines and 
Healthcare products Regulatory Agency and London 
Riverside South West Research Ethics Committee. 
Ethics approval in Australia was from The Eastern 
Health Human Research Ethics Committee. Patients 
provided written informed consent.
Randomisation
We assigned patients (1:1) to either CHOP or GEM-P. 
Randomisation was done centrally by the clinical trials 
unit at the Institute for Cancer Research (ICR) 
independently of the trial team and investigators using a 
minimisation procedure from the beginning of the 
trial and irst patient, without a burn-in period. The 
stratiication variables of locally-determined histological 
subtype and International Prognostic Index risk group 
(low 0–1 vs intermediate 2–3 vs high 4–5) were used for 
computer-based minimisation. We factored in a proba-
bility component (ie, 80% chance of an incoming patient 
being allocated to an unbalanced group). Given the 
diferences in the administration schedules between the 
chemotherapy regimens under assessment, it was not 
possible to mask patients to the treatment they were 
receiving.
Procedures
Patients in the CHOP group received cyclophosphamide 
750 mg/m², doxorubicin 50 mg/m², and vincristine 
1·4 mg/m² (up to a maximum of 2 mg) intravenously on 
day 1, and oral prednisolone 100 mg on days 1–5 every 
21 days, for six cycles. Patients in the GEM-P group 
received intravenous gemcitabine 1000 mg/m² on days 1, 
8, and 15, intravenous cisplatin 100 mg/m² on day 15, 
and oral or intravenous methylprednisolone 1000 mg on 
days 1–5 every 28 days, for four cycles. The rationale for 
administering four cycles of GEM-P (rather than 
six cycles) was that because GEM-P is a platinum-based 
regimen used mainly for patients with relapsed or 
refractory disease, we anticipated that most patients 
would have achieved a maximum response with this type 
of regimen by the fourth cycle.
For both treatment groups, dose modiications were 
required for treatment-related toxicities in accordance 
with the study protocol. Dose banding as per local 
guidelines was permitted. Administration of supportive 
medication, including antiemetic therapy, prophylaxis 
for tumour lysis, granulocyte-colony stimulating factor 
(G-CSF), prophylaxis for Pneumocystis jirovecii 
pneumonia, luid and electrolyte administration relating 
to cisplatin, and administration of prophylaxis for CNS 
relapse, was given in accordance with local practice.
Criteria for withdrawing a patient from study treatment 
were interruption of study treatment for more than 
3 weeks for reasons of toxicity (or for >4 weeks for 
reasons other than toxicity), disease progression, 
withdrawal of consent, unacceptable treatment-related 
toxicity, pregnancy, patient non-compliance, or other 
events precluding further administration of study drugs 
as judged by the study chief investigator (DC).
On completion of study treatment, patients with a 
complete response or unconirmed complete response 
See Online for appendix
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could proceed to high-dose chemotherapy and autologous 
stem-cell transplantation at the local investigator’s 
discretion. Consolidation radiotherapy to sites of initial 
bulk or residual disease was also permitted at the end of 
treatment at the investigator’s discretion.
Patients were assessed at baseline, at each attendance 
for treatment, 30 days after completion of treatment, 
and subsequently every 3 months for 1 year, then every 
6 months until year 2, and every year thereafter for a 
maximum follow-up of 5 years. Laboratory monitoring 
with a full blood-cell count (haemoglobin, white cells, 
neutrophils, and platelets) and biochemistry (sodium, 
potassium, urea, creatinine, calcium, magnesium, 
phosphate, lactate dehydrogenase, total bilirubin, liver 
transaminases, alkaline phosphatase, serum albumin, 
and blood glucose concentrations) were done at 
baseline, on each day of treatment, and at 30 days after 
completion of study treatment. At baseline all patients 
had a contrast enhanced CT scan of the neck, thorax, 
abdomen and pelvis and an ¹⁸F-FDG-PET-CT scan done 
within 28 days of randomisation, and a bone marrow 
biopsy was required within 6 weeks of randomisation. 
CT scans were also required during treatment (after 
cycles 2 and 4 for patients on CHOP and after cycles 1 
and 3 for patients on GEM-P). Both a contrast enhanced 
CT scan and an ¹⁸F-FDG-PET-CT scan were done at the 
end of treatment. Any clinical suspicion of relapse or 
progression was conirmed radiologically or on bone 
marrow aspirate or trephine if disease was marrow-
based only.
All patients enrolled were required to submit their 
diagnostic tissue for central histopathology review 
within 28 days of randomisation; CT and 
¹⁸F-FDG-PET-CT responses were also centrally assessed. 
Site accreditation, data collation, and quality control for 
¹⁸F-FDG-PET-CT imaging was done by the UK PET 
Core Lab (London, UK).
Outcomes
The primary endpoint of the trial was the proportion of 
patients who achieved an investigator-assessed, CT-based 
complete response or unconirmed complete response on 
completion of study chemotherapy, according to the 
International Workshop Standardized Response Criteria 
for non-Hodgkin lymphoma.22
The primary endpoint was locally assessed and analysed 
as randomised in the assessable population, deined as all 
eligible patients who received at least one cycle of treatment 
and had an end of treatment scan or reported clinical 
progression as a reason for stopping trial treatment. A 
patient with no CT imaging but a report of clinical 
progression as reason for stopping trial treatment was 
categorised as having progressed.
A preplanned primary endpoint sensitivity analysis 
was done in the intention-to-treat (ITT) population 
including all eligible patients who received at least one 
cycle of treatment; patients with no end-of-treatment-CT 
assessment were counted as non-responders. A second 
preplanned primary endpoint sensitivity analysis was 
done as treated in the per-protocol population deined as 
all patients who received the planned number of cycles 
and were either assessable by CT or had reported clinical 
progression at the end of treatment.
The secondary endpoints of the trial were overall 
survival, progression-free survival, partial response, stable 
disease, progressive disease, and toxicity, and the propor-
tion of patients with metabolic complete response 
determined by ¹⁸F-FDG-PET-CT, according to the Revised 
Response Criteria for Malignant Lymphoma.23 A secondary 
endpoint assessing ¹⁸F-FDG-PET-CT response speciically 
was deemed to be of particular importance at the time of 
study design, as the role of this outcome in peripheral 
T-cell lymphoma had not previously been assessed in a 
dedicated, prospective cohort of patients with peripheral 
37 assessed for end-of-treatment 
response*
37 assessed for end-of-treatment 
response*
43 assigned to CHOP
42 started treatment
33 completed full treatment
 (1 not assessable for end-of-
 treatment assessment)
87 enrolled and randomly assigned 
1 excluded from the ITT   
 population because of   
 change of diagnosis
9 withdrawn
5 progression (included for 
 end-of-treatment   
 response assessment)
1 toxicity
1 protocol non-compliance  
 (excluded from the ITT  
 analysis)
2 physician’s choice
44 assigned to GEM-P
44 started treatment
26 completed full treatment
18 withdrawn
5 progression  (included   
 for end-of-treatment   
 response assessment)
5 toxicity (3 included   
 for end-of-treatment   
 response assessment)
1 change in diagnosis or 
ineligible (excluded 
from the ITT analysis)
2 death
3 physician’s choice   
 (included for end-of-  
 treatment response   
 assessment)
2 patient’s choice
Figure 1: Trial profile
Toxicity reasons for early study withdrawal were neutropenic sepsis (n=1) in CHOP; and tinnitus (n=2), hearing loss 
(n=1), peripheral neuropathy (n=1), and thrombocytopenia and anaemia (n=1) in GEM-P. Two deaths occurred in the 
GEM-P group, both due to lung infections. One patient chose to discontinue GEM-P and commence CHOP off-study 
at the time of study closure. GEM-P=gemcitabine, cisplatin, and methylprednisolone. CHOP=cyclophosphamide, 
doxorubicin, vincristine, and prednisolone. ITT=intention-to-treat. *Includes three patients with clinical progression.
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T-cell lymphoma. All patients receiving at least one dose 
of study medication were included in the safety analysis 
and analysed as treated. The severity of adverse events was 
deined according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events 
version 4.0. The worst toxicity per organ per patient was 
considered.
A planned subgroup analysis was done to determine the 
factors associated with complete response or unconirmed 
complete response by treatment arm in the assessable 
population with the following factors: peripheral T-cell 
lymphoma subtype, International Prognostic Index, sex, 
B symptoms, age, disease stage, WHO performance 
status, presence of extranodal disease, and raised lactate 
dehydrogenase concentration.
Statistical analysis
We calculated the patient sample size for this trial 
estimating that 50% of patients in the CHOP group and 
70% of patients in the GEM-P group would achieve a 
complete response or unconirmed complete response 
by CT, with an odds ratio of 2·33. We calculated that 
93 patients per group were required to detect this 
diference with 5% signiicance (two-sided) and 
80% power. Continuity correction was not used.
A planned formal interim analysis with 90% power to 
show non-inferiority for review by an independent data 
monitoring committee was due after the irst 51 patients 
in each group had been assessed for end-of-treatment 
response; however, this milestone was not reached as 
the trial closed before accruing 51 patients per group. 
A lower 90% one-sided CI of diference in the number 
of patients achieving a conirmed or unconirmed 
complete response between treatments was expected 
to be greater than 25% (ie, a non-inferiority margin 
of 25%).
The number of patients achieving a complete response 
or unconirmed complete response at the end of study 
chemotherapy was reported by treatment group with 
95% CI using normal approximation and compared 
between groups using logistic regression, with odds ratio 
(OR [95% CI]) for CHOP versus GEM-P. Additionally, 
a logistic regression model was itted to adjust for the 
stratiication variables, with OR (95% CI) for CHOP 
versus GEM-P.
In the planned subgroup analysis, we used logistic 
regression to assess treatment diferences in responses 
within the predeined subgroups, with results displayed 
as ORs in a Forest plot. Progression events were deined 
as clinical or radiological documented disease pro-
gression or death from any cause. Patients recording 
no event were censored at the last follow-up date. 
Progression-free survival and overall survival were 
calculated from the date of randomisation until a 
progression or death event occurred, respectively, using 
Kaplan-Meier methods and compared between groups 
using a log-rank test. Additionally, a Cox proportional 
hazards model was itted to adjust for the stratiication 
variables and to calculate a hazard ratio (HR [95% CI]) for 
CHOP versus GEM-P. The ITT population was used for 
survival analyses.
We assessed the following factors afecting overall sur-
vival and progression-free survival using Cox regression 
CHOP (six 
cycles; n=43)
GEM-P (four 
cycles; n=44)
Sex
    Men 30 (70%) 32 (73%)
    Women 13 (30%) 12 (27%)
Age (years; median IQR) 64 (54–69) 61 (50–70)
Aged >60 years 27 (63%) 24 (55%)
IPI score
0–1 9 (21%) 8 (18%)
2–3 26 (60%) 25 (57%)
4–5 8 (19%) 11 (25%)
Local histology
PTCL not otherwise specified 19 (44%) 18 (41%)
ALK-negative ALCL 6 (14%) 8 (18%)
AITL 17 (40%) 17 (39%)
EATL 1 (2%) 1 (2%)
Hepatosplenic γδ T-cell lymphoma 0 0
Central histology
PTCL not otherwise specified 11 (26%) 10 (23%)
ALK-negative ALCL 4 (9%) 4 (9%)
AITL 22 (51%) 17 (39%)
EATL 1 (2%) 0
Panniculitis-like T-cell lymphoma 0 1 (2%)
PTCL not otherwise specified or 
panniculitis-like T-cell lymphoma
0 1 (2%)
Not assessable 5 11 (25%)
Stage
I 1 (2%) 0
II 8 (19%) 3 (7%)
III 16 (37%) 16 (36%)
IV 18 (42%) 25 (57%)
B symptoms present 26 (60%) 27 (61%)
Increased lactate dehydrogenase 27 (63%) 27 (61%)
Extranodal sites present 25 (58%) 30 (68%)
WHO performance status
0 17 (40%) 21 (48%)
1 19 (44%) 18 (41%)
2 7 (16%) 5 (11%)
Data are n (%) except where indicated otherwise. CHOP=cyclophosphamide, 
doxorubicin, vincristine, and prednisolone. GEM-P=gemcitabine, cisplatin, and 
methylprednisolone. IPI=International Prognostic Index. PTCL=peripheral T-cell 
lymphoma. ALK-negative ALCL=anaplastic lymphoma kinase-negative anaplastic 
large cell lymphoma. AITL=angioimmunoblastic T-cell lymphoma. 
EATL=enteropathy-associated T-cell lymphoma.
Table 1: Baseline characteristics of all randomly assigned patients
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analysis in the ITT population combining both treatment 
groups: age, sex, disease stage, WHO performance 
status, B symptoms, presence of raised lactate dehydro-
genase, International Prognostic Index risk group, 
subtype of peripheral T-cell lymphoma, number of 
extranodal sites, treatment arm, local CT response after 
study chemotherapy, central ¹⁸F-FDG-PET-CT response 
after study chemo therapy, and autologous stem-cell 
transplantation following irst-line treatment. For safety 
analyses, the proportion of patients reporting toxicities of 
grade 3 or worse was compared between groups using a 
χ² test.
The data analysis was generated using Stata version 14. 
The trial was overseen by trial management and trial 
steering committees and an independent data monitoring 
committee. This trial is registered with ClinicalTrials.gov 
(NCT01719835) and the European Clinical Trials Database 
(EudraCT 2011-004146-18).
Role of the funding source
The trial sponsor (The Royal Marsden Hospital, London, 
UK) was responsible for randomisation, data gathering, 
entry, and validation, reports of serious adverse events, 
organisation of the central histopathology review and 
central response assessment, statistical analysis, and 
production of the report. The funder of the study had no 
role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had inal responsibility for the decision to 
submit for publication.
Results
Between June 18, 2012, and Nov 16, 2016, we randomly 
assigned 87 patients to study treatment, 43 to CHOP and 
44 to GEM-P (igure 1). Before the formal interim 
analysis, interim results from a planned unmasked 
independent review of eicacy data by the independent 
data monitoring committee in November, 2016, showed 
that fewer patients had achieved a complete response or 
unconirmed complete response with GEM-P than with 
CHOP. The committee concluded there was a high 
likelihood that GEM-P would be inferior to CHOP at the 
end of the trial, as indicated by the one-sided 80% CI for 
diference. The trial was subsequently closed to 
recruitment and all patients treated in the GEM-P group 
were ofered the option to change to CHOP of-study at 
the time of study closure as per the recommendations of 
the data monitoring committee and trial management 
group. The last dose of study treatment on trial was 
administered on Feb 23, 2017.
Patient baseline and disease characteristics were well 
balanced between groups (table 1). All 71 patients with 
suicient tissue for central histopathology review had 
the diagnosis of peripheral T-cell lymphoma conirmed 
centrally, although the subtype of peripheral T-cell 
lymphoma was revised for 16 patients (23%).
After receiving four cycles of GEM-P, one patient in the 
GEM-P group received an additional two cycles for 
persistent bone marrow iniltration before autologous 
stem cell transplantation. 16 patients (38%) of 42 treated 
with CHOP and 23 (52%) of 44 treated with GEM-P had 
at least one treatment delay, and 18 patients (43%) of 
42 treated with CHOP and 21 (48%) of 44 treated with 
GEM-P had at least one dose reduction on study. Median 
total dose received and dose intensities for each drug by 
treatment group are in table 2.
The proportions of CHOP and GEM-P treatments 
requiring G-CSF support were 135 (62%) of 219 and 
70 (54%) of 130, respectively. Two patients (5%) of 43 in 
the CHOP group and four (9%) of 44 in the GEM-P group 
received prophylaxis for CNS relapse during the study: 
four (9%) received intrathecal methotrexate, one (2%) 
received intrathecal methotrexate plus methotrexate, 
cytarabine, and hydrocortisone, and one (2%) received 
unspeciied therapy.
Investigator-assessed end of treatment response by 
contrast-enhanced CT was available for 74 patients 
(37 in each group; table 3). At a median follow-up of 
CHOP GEM-P
Cyclophosphamide Doxorubicin Vincristine Prednisolone Gemcitabine Cisplatin Methylprednisolone
Total dose received (mg) 7960 (5080–8760) 540 (342–588) 12 (7–12) 2400 (1500–3000) 18262·5 (7060–21900) 361·5 (201·5–707·5) 20 000 (7500–20 000)
Relative dose intensity 98·1 (90·5–100) 97·9 (91·9–100·0) 99·2 (85·7–100·0) 97·0 (89·7–100·0) 86·5 (69·2–95·9) 82·2 (41·6–97·4) 98·1 (83·3–100·0)
Data are median (IQR).
Table 2: Total chemotherapy dose received by patients and dose intensity achieved
CHOP (six cycles; 
n=43)
GEM-P (four cycles; 
n=44)
Overall response 28 (75·7) 25 (67·6)
Complete response or unconfirmed complete response* 23 (62·2) 17 (45·9)
Partial response 5 (13·5) 8 (21·6)
Stable disease 2 (5·4) 3 (8·1)
Progressive disease 4 (10·8) 6 (16·2)
Progressive disease assessed clinically 3 (8·1) 3 (8·1)
Not done or not assessable 6 7
Data are n (%) of those who had an assessment. CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisolone. 
GEM-P=gemcitabine, cisplatin, and methylprednisolone. *p=0·164.
Table 3: End of treatment response by CT
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27·4 months (IQR 16·6–38·4), 23 patients (62%) of 
37 assigned to CHOP had achieved a complete response 
or unconirmed complete response compared with 
17 (46%) of 37 assigned to GEM-P (OR 0·52, 95% CI 
0·21–1·31; p=0·164; adjusted OR for stratiication factors 
0·53 (0·19–1·46, p=0·22). Given the higher proportion of 
patients with stage IV disease in the GEM-P group versus 
CHOP, the logistic regression was adjusted for stage as 
well as for stratiication variables, but this did not make 
any diference to the complete response outcome by 
randomisation result (OR 0·50, 95% CI 0·18–1·40; 
p=0·19). Sensitivity analyses of the primary endpoint in 
both the ITT and per-protocol populations showed no 
diferences between the treatment groups (appendix p 3). 
The inferiority of complete response outcomes with 
GEM-P was consistent across subgroups (igure 2).
After chemotherapy, four (9%) of 43 patients in the 
CHOP group underwent radiotherapy; no patients 
in the GEM-P arm received radiotherapy. Stem cells 
were collected for 16 patients (37%) of 43 in the CHOP 
group and 15 (34%) of 44 in the GEM-P group, with 
11 (26%) in CHOP and 13 (30%) in GEM-P proceeding 
to autologous stem-cell transplantation in irst remis-
sion. Second-line chemotherapy was administered to 
15 patients (35%) of 43 in the CHOP group and 20 
(45%) of 44 in the GEM-P group.
Survival was assessed in the ITT population (84 patients 
[97%] of 87). Three patients (two in the CHOP group, one 
in the GEM-P group) were excluded from the ITT 
population following treatment assign ment, two because 
of a change in diagnosis from peripheral T-cell lymphoma 
not otherwise speciied to Hodgkin’s lymphoma after 
randomisation and a third patient was deemed to be 
ineligible following treatment assignment because of 
cardiac impairment. 2-year progression-free survival was 
38·0% (95% CI 22·9–52·9) in the GEM-P group and 
36·6% (21·4–52·0) in the CHOP group (HR 1·07, 95% CI 
0·61–1·85, p=0·82; appendix p 4). Two patients (2%) of 
84 had CNS relapses (both isolated CNS recurrences); 
both patients had peripheral T-cell lymphoma not 
otherwise speciied, were treated with CHOP, and 
developed progression in the CNS after cycle 1 and 
cycle 5, respectively. 2-year overall survival was 63·9% 
(95% CI 45·7–77·4) in the GEM-P group and 51·0% 
(32·8–67·4) in the CHOP group (HR 0·69, 95% CI 
0·35–1·38, p=0·30; appendix p 5).
ALK negative ALCL (central)
AITL (central)
PTCL NOS or EATL  (central)
IPI risk group
   0–1
   2
   3 
   4–5
Sex
   Male
   Female 
B symptoms absent 
B symptoms present 
Age
   ≤60 years 
   >60 years 
Stage I/II 
Stage III 
Stage IV 
WHO performance status 0 
WHO performance status 1 
Extranodal sites absent 
Extranodal sites present
Lactate dehydrogenase not elevated
Lactate dehydrogenase elevated
All
 4/4 (100%)
 21/38 (55%)
 8/18 (44%)
            
 10/12 (83%)
 15/26 (58%)
 10/20 (50%)
 5/16 (31%)
 30/52 (58%)
 10/22 (45%)
 19/29 (66%)
 21/45 (47%)
 15/31 (48%)
 25/43 (58%)
 5/7 (71%)
 16/27 (59%)
 19/40 (48%)
 23/33 (70%)
 13/32 (41%)
 17/27 (63%)
 23/47 (49%)
 21/28 (75%)
 19/66 (41%)
 40/84 (48%)
GEM-P betterCHOP better
Odds ratio (95% Cl)
1·0 1·6 3·2 6·40·01 0·05 0·2 0·4 0·8 
Events/patients (%) Odds ratio (95% CL) p value
 ..
0·692 (0·189–2·553)
0·036 (0·003–0·484)
 1·00 (0·048–20·83)
 1·050 (0·220–5·003)
 0·667 (0·113–3·919)
 0·055 (0·004–0·805)
0·529 (0·174–1·615)
0·476 (0·086–0·395)
 2·063 (0·434–9·804)
0·200 (0·056–0·713)
 0·889 (0·216–3·662)
 0·358 (0·102–1·251)
 0·250 (0·007–8·560)
1·200 (0·257–5·593)
0·363 (0·101–1·316)
 0·727 (0·161–3·281)
0·563 (0·134–2·362)
 1·687 (0·346–8·222)
0·267 (0·080–0·891)
1·212 (0·216–6·800)
0·343 (0·102–1·158)
0·52 (0·21–1·31)
 ..
0·578
0·012
 1·00
0·951
0·654
0·034
0·264
0·395
0·363
0·013
0·870
0·107
0·442
0·816
0·123
0·679
0·432
0·517
0·032
0·827
0·085
0·164
Figure 2: Factors potentially predictive of a complete response or unconfirmed complete response
Data are from an analysis of outcomes at end of treatment. CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisolone. GEM-P=gemcitabine, cisplatin, and 
methylprednisolone. ALK-negative ALCL= anaplastic lymphoma kinase-negative anaplastic large cell T-cell lymphoma. AITL=angioimmunoblastic T-cell lymphoma. PTCL 
NOS=peripheral T-cell lymphoma not otherwise specified. EATL=enteropathy-associated T-cell lymphoma. IPI=International Prognostic Index. ··=data not obtainable. 
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Signiicant risk factors associated with superior overall 
survival in univariable analysis (appendix p 6) were a 
complete response or unconirmed complete response 
on completion of treatment determined by CT, a 
complete response on completion of treatment 
determined by ¹⁸F-FDG-PET-CT, and autologous stem-
cell trans plantation consolidation in irst remission. 
No factor remained independently prognostic for over-
all survival in multivariable analysis (appendix p7). 
Presence of raised lactate dehydrogenase, an 
International Prognostic Index score of more than 1, 
and presence of more than one extranodal site 
was associated with inferior progression-free survival 
in univariable analysis (appendix p 8), while patients 
with a complete response or unconirmed complete 
response to induction determined by CT or a complete 
response to induction determined by ¹⁸F-FDG-PET-CT 
or undergoing auto logous stem-cell transplantation 
consolidation in irst remission had superior 
progression-free survival. In multivariable analysis 
presence of raised lactate dehydro genase concentrations 
at diagnosis was independently associated with inferior 
progression-free survival; by contrast, attainment of a 
complete response by ¹⁸F-FDG-PET-CT to study treat-
ment or presence of a low or low-intermediate risk 
international prognostic index score was independently 
associated with superior progression-free survival 
(appendix p9)
Two patients (5%) died during the study, both in the 
GEM-P group, from lung infections. Up to Nov 7, 2017, 
33 patients (39%) of 84 had died in the ITT population, 
18 (44%) of 41 in the CHOP group (13 from disease 
progression and ive from sepsis) and 15 (35%) of 43 in 
the GEM-P group (nine from disease progression, three 
from sepsis, one cardiac event, one from ischaemic colitis 
and disease progression, and one from metastatic cancer).
Safety was assessed for 86 patients (99%) who received 
a dose of study treatment. CHOP was associated with 
more febrile neutropenia of all grades (table 4). GEM-P 
was associated with more thrombocytopenia of all 
grades and grade 3 or worse; however, thrombocytopenia 
was not associated with increased bleeding. GEM-P was 
also associated with more tinnitus. There were 
38 serious adverse events in the CHOP group and 
43 in the GEM-P group. 
In the ¹⁸F-FDG-PET-CT substudy, 79 (91%) of 87 patients 
assessed had FDG-avid disease at baseline on central 
review of imaging. End-of-treatment response by 
¹⁸F-FDG-PET-CT or CT was assessable in 70 patients 
(89%) of 79 (appendix p 10); although the incidence of 
complete response as determined by ¹⁸F-FDG-PET-CT 
was lower in the GEM-P group than in the CHOP group, 
the diference between groups was less marked than 
between-group diferences for complete response 
assessment by  contrast-enhanced CT. The proportion of 
agreement between ¹⁸F-FDG-PET-CT and contrast-
enhanced CT for deter mining a complete response was 
77·3%. For 40 patients with a complete response by 
¹⁸F-FDG-PET-CT on com pletion of study treatment, the 
corresponding contrast-enhanced CT data were: 24 (60%) 
with a complete response, seven (18%) with an uncon-
irmed complete response, ive (13%) with a partial 
response, two (5%) with stable disease, and two (5%) with 
progressive disease.
CHOP (n=42) GEM-P (n=44)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Acute renal toxicity 0 0 0 1 (2%) 1 (2%) 0
Alopecia* 27 (64%) 0 0 12 (27%) 0 0
Anaemia 23 (55%) 4 (10%) 0 22 (50%) 5 (11%) 1 (2%)
Constipation 18 (43%) 0 0 20 (45%) 1 (2%) 0
Cerebrovascular accident 0 0 0 0 0 1 (2%)
Diarrhoea 15 (36%) 0 0 13 (30%) 2 (5%) 0
Dyspnoea 4 (10%) 0 0 6 (14%) 0 0
Fatigue 29 (69%) 2 (5%) 0 35 (80%) 0 0
Febrile neutropenia† 0 10 (24%) 2 (5%) 1 (2%) 3 (7%) 0
Fever 11 (26%) 3 (7%) 0 11 (25%) 2 (5%) 1 (2%)
Haemorrhage 4 (10%) 0 0 7 (16%) 0 1 (2%)
Headache* 4 (10%) 0 0 13 (30%) 0 0
Hyperglycaemia 1 (2%) 1 (2%) 0 3 (7%) 1 (2%) 0
Hypertension 1 (2%) 1 (2%) 0 3 (7%) 1 (2%) 0
Hypotension 3 (7%) 1 (2%) 0 5 (11%) 1 (2%) 0
Indigestion 14 (33%) 0 0 8 (18%) 0 0
Infection 8 (19%) 7 (17%) 0 14 (32%) 4 (9%) 2 (5%)
Infusion reaction 1 (2%) 0 0 1 (2%) 1 (2%) 0
Mood disturbance 6 (14%) 0 0 7 (16%) 1 (2%) 0
Mucositis* 20 (48%) 1 (2%) 0 11 (25%) 0 0
Nausea 17 (40%) 0 0 22 (50%) 1 (2%) 0
Neuropathy 11 (26%) 1 (2%) 0 7 (16%) 0 0
Neutropenia 5 (12%) 2 (5%) 15 (36%) 7 (16%) 5 (11%) 4 (9%)
Pulmonary embolus 0 2 (5%) 1 (2%) 0 1 (2%) 0
Pruritus 7 (17%) 0 0 9 (20%) 0 0
Skin rash 7 (17%) 0 0 12 (27%) 0 0
Thrombocytopenia† 8 (19%) 1 (2%) 3 (7%) 16 (36%) 8 (18%) 5 (11%)
Tinnitus* 1 (2%) 0 0 12 (27%) 0 0
Vomiting 12 (29%) 1 (2%) 0 13 (30%) 2 (5%) 0
Weight loss 10 (24%) 1 (2%) 0 9 (20%) 1 (2%) 0
Other toxicity 23 (55%) 5 (12%) 1 (2%) 27 (61%) 9 (20%) 2 (5%)
Data are n (%) for adverse events of grade 1–2 occurring in at least 10% of patients and all grade 3–5 events. 
Two patients (5%) died during the study, both in the GEM-P group, from lung infections. Other adverse events with 
CHOP of grade 3 or worse were superior mesenteric artery thrombosis (grade 3), muscle weakness (grade 3), insomnia 
(grade 3), hyponatraemia (grade 4), tumour lysis (grade 3), pain left hip and legs (grade 3), swelling in left knee 
(grade 3), and squamous cell carcinoma cheek (grade 3). Other adverse events with GEM-P of grade 3 or worse were 
right flank pain (grade 3), abdominal pain (grade 3), colonic perforation (grade 4), hip pain (grade 3), chest pain (grade 
3), chest/abdominal pain (grade 3), paraneoplastic occurrence (grade 4), raised alanine transaminase (grade 3), bone 
pain (grade 3), dehydration (grade 3), hypokalaemia (grade 3), raised alanine transaminase (grade 3), and cellulitis 
(grade 3). CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisolone. GEM-P=gemcitabine, cisplatin, and 
methylprednisolone. *p<0.05 for all grades. †p<0.05 for all grades and grade 3 or worse. 
Table 4: Adverse events by treatment
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Discussion
The number of complete responses or unconirmed 
complete responses in the GEM-P group was non-
signiicantly inferior to the CHOP group, indicating that 
the primary endpoint of the trial would not be met. A 
planned subgroup analysis showed that the efect was 
consistent across subgroups. 
As part of a preplanned analysis, we also assessed the 
proportion of agreement between contrast-enhanced CT 
and ¹⁸F-FDG-PET-CT for determining a complete 
response, and found it to be around 77%. This discrepancy 
was probably mainly due to the presence of persistent 
non-FDG-avid nodes discernible on contrast-enhanced 
CT after chemotherapy and ¹⁸F-FDG-PET-CT might be 
better able to distinguish between a residual ibrotic 
mass following chemotherapy versus viable tumour in 
peripheral T-cell lymphoma. The rate of early withdrawal 
before completing study treatment for reasons other 
than disease progression was higher in the GEM-P group 
with more participants withdrawing for toxicity and by 
choice; there were also two deaths on treatment with 
GEM-P, both due to lung infections. Patients treated in 
the CHOP group had more febrile neutropenia than 
those in the GEM-P group; by contrast, patients treated 
with GEM-P had more thrombocytopenia of all grades 
and grade 3 or worse than those treated with CHOP, 
although this did not lead to a substantial increase in 
bleeding events. GEM-P was also associated with a 
signiicant increased risk of grade 1-2 tinnitus, which led 
two patients to withdraw early from the study.
Relative dose intensity was lower in the GEM-P group 
than in the CHOP group, although this might mainly 
relect the dose modiications that were required with the 
GEM-P regimen according to blood results on the day of 
treatment. However, there were two separate instances 
where a day of GEM-P treatment was incorrectly omitted 
rather than delayed, resulting in two protocol violations, 
although it seems unlikely that this modiication would 
have signiicantly negatively afected the primary 
endpoint assessment in the GEM-P arm. At the median 
follow-up of 27·4 months there was no diference in 
either 2-year progression-free survival or overall survival 
between the treatment groups. In a Cox regression 
analysis of the ITT population, signiicant risk factors 
associated with superior overall survival included a 
complete response at end of treatment determined either 
by CT or by ¹⁸F-FDG-PET-CT, and autologous stem-cell 
transplantation consolidation in irst remission in 
univariable analysis. However, no factors remained 
independently signiicant for overall survival in multi-
variable analysis. In multivariable analysis of the factors 
associated with progression-free survival, presence of 
a raised lactate dehydrogenase concentration at pre-
sentation was prog nostic of inferior progression-free 
survival, whereas a low or low-intermediate risk 
international prognostic index score or a complete res-
ponse to study treatment determined by ¹⁸F-FDG-PET-CT 
was independently associated with superior progression-
free survival.
The number of patients who withdrew from the study 
for reasons other than disease progression was higher in 
the GEM-P group than in the CHOP group, and 
consequently more patients receiving GEM-P proceeded to 
second-line chemotherapy. This might explain the absence 
of a survival diference between arms at this time, as the 
numbers undergoing autologous stem-cell transplantation 
in irst remission were similar between groups, although 
this remains to be further investigated. However, given 
that the inferior incidence of complete responses and 
unconirmed complete responses in the GEM-P group 
was not associated with inferior progression-free survival 
or overall survival for these patients, complete response 
(particularly when assessed by contrast-enhanced CT) 
might not be an accurate surrogate endpoint in peripheral 
T-cell lymphoma. Future studies in this area should 
therefore better investigate this point, and perhaps should 
be designed with primary endpoints that incorporate 
survival. Indeed, measuring endpoints such as 24-month 
event-free survival in peripheral T-cell lymphoma might be 
an important predictor of overall survival; one study 
showed that patients achieving 24-month event-free 
survival had superior overall survival compared with those 
who did not reach this milestone.24
Although our study closed early to recruitment, this 
phase 2 trial is an important addition to the prospective 
evidence-base for this rare subtype of non-Hodgkin 
lymphoma and is, to our knowledge, the third ran domised 
trial reported with treatment-naive patients with 
peripheral T-cell lymphoma. All participants had the 
diagnosis and subtype of peripheral T-cell lymphoma 
conirmed centrally by two expert lymphoma pathologists; 
for around 23% of patients with peripheral T-cell 
lymphoma the subtype was revised, highlighting that 
there are challenges to accurately diagnosing peripheral 
T-cell lymphoma. Additionally, although extensive future 
work is necessary, our study reports, to our knowledge, the 
irst dedicated prospective trial to assess ¹⁸F-FDG-PET-CT 
responses in patients with peripheral T-cell lymphoma, all 
of which were done at accredited sites, underwent central 
quality control, and were centrally assessed by an expert 
¹⁸F FDG PET-CT physician. Our study also adds important 
data from a prospective trial cohort on the incidence of 
CNS relapse in peripheral T-cell lymphoma, which at the 
time of writing has been reported in two patients with 
peripheral T-cell lymphoma not otherwise speciied and 
occurred during study treatment.
However, the limitations of our study also need to be 
acknowledged. Firstly, and most importantly, as the trial 
closed early to recruitment it was not adequately powered 
to assess the primary study endpoint. Another potential 
limitation of the study is in the interpretation of dose 
intensity for GEM-P; this regimen was administered 
weekly for 3 weeks out of 4, with the dose adjusted on 
each day of treatment in accordance with the blood 
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counts on the day of treatment, which is in contrast to 
CHOP where treatment is administered once every 
3 weeks allowing more time for count recovery.
Despite the absence of international consensus on the 
gold-standard therapy for previously untreated patients 
with peripheral T-cell lymphoma, CHOP has been 
adopted by many countries as the reference regimen.25 
With the exception of ALK-positive anaplastic large cell 
T-cell lymphoma26 the outcomes with CHOP or CHOP-
like therapy appear to be suboptimum, with a 5-year 
overall survival of only 38·5%, as reported in a meta-
analysis.5 Attempts to surpass outcomes with CHOP 
have proven largely unsuccessful, except a subgroup 
analysis by the German High-Grade NHL Study Group 
that showed improved event-free survival but no overall 
survival beneit with CHOEP for younger patients 
(≤60 years) with peripheral T-cell lymphoma with 
normal lactate dehydrogenase concentrations treated 
within aggressive non-Hodgkin lymphoma clinical 
trials.6 Therefore, optimising therapy for newly 
diagnosed patients remains an important unmet 
medical need.
MDR-1/Pgp is known to be overexpressed in peripheral 
T-cell lymphoma7,8 in the lymphoma cells, residual 
lymphocytes, and endothelium,8 and this might account 
for the reported eicacy of the nucleoside analogue 
gemcitabine in peripheral T-cell lymphoma, which is not 
a substrate of the elux pump.27 The activity of intravenous 
gemcitabine monotherapy (1200 mg/m² on days 1, 8, and 
15 of a 28-day cycle) was irst reported in 1998 in a phase 2 
study9 of 13 patients with relapsed or refractory peripheral 
T-cell lymphoma unspeciied or patients with mycosis 
fungoides with an objective response of 69% and 
complete response of 8%. Similar eicacy was shown in 
another study10 (objective response 60% and complete 
response 20%) in a cohort of ten patients with relapsed or 
refractory T-cell lymphoma using the same dosing 
schedule. A subsequent study in 2010 conirmed this 
eicacy (objective response 51%, complete response 23%) 
in a larger number of relapsed or refractory patients (n=39) 
with some durable remissions.11
Various combinations of gemcitabine with platinum 
and steroid in relapsed or refractory peripheral T-cell 
lymphoma have also been reported in the scientiic 
literature with encouraging results (objective response 
36%–100%) and acceptable toxicity.12–20,28 Speciically, the 
GEM-P regimen has been assessed in three retrospective 
studies including patients with peripheral T-cell 
lymphoma, predominantly with relapsed or refractory 
disease, with reported objective responses of 69%–100% 
(complete response 19%–50%) and some durable 
remisisons.14–16 Furthermore, some novel regimens incor-
porating gemcitabine have been assessed in treatment-
naive patients in the peripheral T-cell lymphoma 
setting,4,8,29,30 including one randomised trial,4 and all have 
shown encouraging results for gemcitabine in this 
indication excepting one.8 In one trial, patients were 
assigned either to CHOP (n=51) or a combination of 
gemcitabine 800 mg/m² on days 1 and 8, cisplatin 
25 mg/m² intra venously on days 1–3, prednisolone 
60 mg/m² orally on days 1–5, and thalidomide 200 mg 
orally once per day continuously (n=52); this regimen was 
associated with a signiicant improvement in the 
proportion of patients achieving a response, 2-year 
progression-free survival, and 2-year overall survival.4
Our study conirms the poor outcomes for patients 
with peripheral T-cell lymphoma in the setting of a 
prospective randomised trial.5,25 Recruitment to the trial 
was closed early as there was strong evidence that the 
primary endpoint—to detect superiority of GEM-P over 
CHOP by a comparison of the CT-based complete 
responses and unconirmed complete responses at end 
of treatment—would not be met, although this was not 
relected in inferior progression-free survival or overall 
survival at 2 years in the GEM-P group. More patients 
also withdrew from the GEM-P group than from the 
CHOP group for reasons other than disease progression. 
The dose of cisplatin 100 mg/m² administered in GEM-P 
was associated with more grade 1–2 tinnitus (compared 
with CHOP), which led three patients to withdraw early 
before completing study treatment; this dose therefore 
appears to be at the upper limit of what is tolerable in 
terms of ototoxicity, but further assessment of the dosing 
limit would be necessary to establish tolerability. 
Nevertheless,  we have revised the dose of cisplatin 
administered with GEM-P at The Royal Marsden 
Hospital (London, UK) to a total dose of 75 mg/m², in 
line with the dose used in other regimens containing 
gemcitabine and platinum,4,31 with the expectation that 
this might reduce the incidence of ototoxicity.
Although our data show that GEM-P has eicacy in 
terms of response and survival in peripheral T-cell 
lymphoma, in our randomised study it was inferior to 
CHOP for treatment-naive patients with this disease. 
One possible exception for the use of this type of regimen 
upfront might be when front-line anthracycline-based 
chemotherapy is contraindicated to avoid cardiotoxicity. 
In conclusion, although further studies are warranted, 
our phase 2 randomised trial suggests that CHOP 
should, for the time being, remain the reference regimen 
for previously untreated patients with peripheral T-cell 
lymphoma and that GEM-P is best reserved for the 
relapsed and refractory setting at present.
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